Key contacts

Will Corkill

Will Corkill
Director

Simon Wilson

Simon Wilson
Director

Regional office - Australia
Level 25
Aurora Place
88 Phillip Street
Sydney
NSW 2000
Australia
Tel: +61 (0)2 9258 1161

Regional office - New Zealand
Level 15
171 Featherston Street
Wellington 6011
New Zealand
Tel: +64 (0)4 8948555

swilson@edisongroup.com
wcorkill@edisongroup.com

listed companies

Range Resources Nkwe Platinum
MEC Resources Coal of Africa
Syndicated Metals Gold One
Bionomics Allied Gold Mining
Phylogica ADX Energy
Alkane Resources Bellzone Mining
Sumatra Copper & Gold Continental Coal
Gunson Resources RedFlow
Lochard Energy Circadian Technologies
Universal Coal Biotron
See more

Companies with HQs in asia-pacific

Seeing Machines Forterra Trust
Greka Drilling Bezant Resources
Green Dragon Gas Baobab Resources
Endace Wynnstay Group
PXP Vietnam Fund Chatham Rock Phosphate
Tenon MMG
SeaDragon Contact Energy
Cue Energy New Zealand Oil & Gas
Rubicon Sky Network Television
Pura Vida Energy Sealegs Corporation
See more

Latest research

Alkane Resources

TGO costs halved, DZP all but gets thumbs up

Update | Mining | 16/09/2014

Alkane’s Tomingley Gold Operations (TGO) gold mine has materially improved in terms of its operational performance quarter-on-quarter. Its all-in sustaining costs of production are down 47% from end year FY14 and upgrades to its resources (up 2.2%) and reserves (up a significant 41%) estimates are positive for the TGO’s profitability and mine life. The NSW authorities have conditionally approved the Dubbo Zirconia Project (DZP) (although final clarification is still required and is expected…

Imugene

Progressing HER-Vaxx into a gastric Phase II

QuickView | Pharmaceutical & Healthcare | 15/09/2014

Imugene is developing a Phase II in second-line cancer for its acquired HER-Vaxx therapeutic vaccine targeting HER2+ gastric cancer patients. HER-Vaxx may replicate the antibody combination of Herceptin and Perjeta (Roche) that shows impressive survival efficacy in breast cancer. Gastric cancer is seen as a more promising large, poorly-served market. Phase I (in breast cancer) showed safety with the virosome-based vaccine stimulating good antibody responses in eight of 10 patients. The Phase II trial…

TZ Limited

Unlocking its potential

Initiation | Technology | 11/09/2014

After a major restructure and rebuilding of the business in 2009, TZ seems to be turning the corner. There is strong growth in both its infrastructure protection (IXP) and packaged asset delivery (PAD) divisions, and with operational leverage, numerous significant contract opportunities and potential to license its technology to third parties there are many reasons to be optimistic. The timing and value of contracts are difficult to predict, but given the expanded roll-out potential with its already…

Seeing Machines

Daily comment

Institutional Comment | Technology | 10/09/2014

Seeing Machines

Formalising a relationship with Samsung

Flash note | Technology | 08/09/2014

Seeing Machines (SM) has signed an MOU with Samsung Electro-Mechanics Corporation (SEMCo) to jointly development face and eye tracking technology for the consumer electronics industry. Having worked with SM for nearly two years, SEMCo says it regards SM’s eye-tracking algorithms as industry best. The signing of the MOU takes the relationship to the next stage, enabling the partners to examine commercial opportunities for SM’s IP across Samsung’s entire range of products. However,…

About

Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports